Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00366262 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

A Phase 1 study of Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00366262 is a Phase 1 study of Healthy that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00366262, a Phase 1 study of Healthy, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Naproxen
  • DRUG PLA-695

Study Locations (1)

Texas

  • - Houston

Trial Details

FieldValue
Start Date 2006-06
Est. Completion 2007-03
Phase Phase 1

What the Registry Record Tells You About NCT00366262

The ClinicalTrials.gov registry entry for NCT00366262 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00366262 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00366262 about?

NCT00366262 is a clinical study titled "Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen". The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

What is the current status of trial NCT00366262?

This trial is currently completed. It is a Phase 1 study. The study started on 2006-06. Estimated completion is 2007-03.

What conditions does trial NCT00366262 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00366262?

The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), PLA-695 (DRUG).

Who is sponsoring clinical trial NCT00366262?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00366262 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.